CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer

CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer

Thanks to its very high genome-editing efficiency, CRISPR-Cas9 technology could be a promising anticancer weapon. Clinical trials using CRISPR-Cas9 nuclease to ex vivo edit and alter immune cells are ongoing. However, to date, this strategy still has not been applied in clinical practice to directly...

Full description

Saved in:
Bibliographic Details
Main Authors: Julian Boutin, Coralie Genevois, Franck Couillaud, Isabelle Lamrissi-Garcia, Veronique Guyonnet-Duperat, Alice Bibeyran, Magalie Lalanne, Samuel Amintas, Isabelle Moranvillier, Emmanuel Richard, Jean-Marc Blouin, Sandrine Dabernat, François Moreau-Gaudry, Aurélie Bedel
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
cancer gene therapy
CRISPR
porphyrin
UROS
porphyria
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329924000146
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950329924000146

Similar Items